Julie Shapiro, DO
Infectious Disease · Bridgeton, MONPI 1831486364
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,181 of the $3,626 with a category attached, or 87.7%. It is spread thinly across 18 manufacturers, the largest accounting for just 21.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $832 and has fallen 64.5% since, to $295 in 2025.
Across 189 payments — averaging $19.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$776
- Viiv Healthcare Company$742
- Astellas Pharma US Inc$421
- Gilead$308
- Insmed, Inc.$228
- AbbVie$205
- plus $946 from 12 others
What the payments were for
- Food & beverage$3,18188%
- Education$44512%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 41 | $776 |
| Viiv Healthcare Company | 47 | $742 |
| Astellas Pharma US Inc | 10 | $421 |
| Gilead | 15 | $308 |
| Insmed, Inc. | 14 | $228 |
| AbbVie(2 entities) | 12 | $205 |
| Cumberland Pharmaceuticals, Inc. | 13 | $202 |
| Shionogi Inc | 11 | $200 |
| Melinta Therapeutics, LLC | 7 | $125 |
| Aimmune Therapeutics, Inc. | 4 | $103 |
| Theratechnologies Inc. | 2 | $79 |
| Paratek Pharmaceuticals, Inc. | 4 | $67 |
| EMD Serono, Inc. | 2 | $48 |
| Johnson & Johnson | 3 | $44 |
| Vyera Pharmaceuticals, LLC | 1 | $25 |
| Pfizer | 1 | $23 |
| Nestle Healthcare Nutrition Inc. | 1 | $16 |
| Tetraphase Pharmaceuticals, Inc. | 1 | $14 |
How this compares
$3,626 in reported general payments places this provider in the 80th percentile of 177 infectious disease providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErtapenemErtapenem Sodium | 54 | $12,830 |
| Daptomycin | 53 | $10,694 |
| Cefepime Hcl | 60 | $10,337 |
| CeftriaxoneCeftriaxone Sodium | 207 | $10,022 |
| Ampicillin Sodium | 56 | $6,995 |
| Vancomycin Hcl | 46 | $5,990 |
| MicafunginMicafungin Sodium | 30 | $5,433 |
| Meropenem | 27 | $2,305 |
| Sodium Chloride0.9 % Sodium Chloride | 12 | $596 |
| Doxycycline Hyclate | 15 | $408 |
| Amoxicillin | 28 | $337 |
| Cefdinir | 25 | $275 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 18 | $219 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Bridgeton
- Adnan SiddiquiBridgeton$6K
- Molly Caldwell McMillanBridgeton$2K
- Robert BelsheSaint Louis$382K
- Erik DubberkeSaint Louis$144K
- Rupa PatelSaint Louis$96K
- Michael DiamondSaint Louis$44K
- Nirmol PhilipChesterfield$31K
- Andrej SpecSaint Louis$26K
- William PowderlySaint Louis$20K
- Daniel HoftSt Louis$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.